A main theory behind the cause of Alzheimer’s disease is the build-up of the protein amyloid-beta in the brain. Researchers from the University of Cincinnati provide evidence suggesting it’s the ...
Early in Alzheimer’s disease, your brain can begin to change long before anyone notices a lost name or missed appointment.
Piller is an investigative journalist for Science. In November 2022, Dennis Selkoe, a Harvard professor of neurologic diseases and among the most celebrated and prolific Alzheimer’s researchers, ...
An experimental drug appears to reduce the risk of Alzheimer's-related dementia in people destined to develop the disease in their 30s, 40s or 50s, according to the results of a new study. The ...
In an unprecedented large-scale study, researchers have mapped out the first molecular events that cause harmful protein buildups in the brain of people with Alzheimer's disease. "By measuring the ...
Boca Raton, Florida, June 10, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the ...
Selkoe is co-director of the Ann Romney Center for Neurologic Diseases, Department of Neurology, Mass General Brigham, and Vincent and Stella Coates professor of neurologic diseases at Harvard Medical ...
AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial Lausanne, Switzerland, January 26, 2023 – AC Immune ...
Medications like lecanemab (Leqembi) and donanemab (Kisunla) target amyloid plaques in the brain that build up due to Alzheimer’s disease. They may help slow disease progression for people in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results